Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A multitargeting approach rewires cell identity in fusion-negative rhabdomyosarcoma [snRNAseq and scATACseq]

ABSTRACT: A multitargeting approach rewires cell identity in fusion-negative rhabdomyosarcoma [snRNAseq and scATACseq]

PROVIDER: PRJNA1189452 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

A multitargeting approach rewires cell identity in fusion-negative rhabdomyosarcoma

Project description:A multitargeting approach rewires cell identity in fusion-negative rhabdomyosarcoma

| PRJNA1155672 | ENA

A multitargeting approach rewires cell identity in fusion-negative rhabdomyosarcoma [snRNAseq and scATACseq]

Project description:Rhabdomyosarcoma (RMS), the most common soft-tissue sarcoma occurring in the pediatric population, arises from the skeletal muscle compartment. Several transcriptional and post-transcriptional regulators lock the tumor in a continuous undifferentiated state and prevent the cells from returning to quiescence. MicroRNAs (miRNAs) are short non-coding RNAs that modulate cell identity by means of post-transcriptional regulation of messenger RNAs. In this study, we aimed at identifying miRNAs that could affect FN-RMS cell identity. Thus, we analyzed publicly available datasets and identified miR-449a and miR-340 as the main regulators of cell cycle and p53 signaling. Using miR-eCLIP technology, we identified the direct effects of miRNAs in FN-RMS cell lines, and an overall rewiring of cell identity at the transcriptomic, epigenetic and metabolic level. We observed that miR-449a+340 directly and indirectly targeted glycolysis and pyruvate entry into mitochondria by inhibiting mitochondrial pyruvate complex (MPC) inhibition. The pharmacological inhibition of MPC resulted in a similar metabolic shift with cell cycle exit and a significant reduction in metastatic potential of FN-RMS models. In conclusion, the combination of miR-449 and miR-340 play a pivotal role in orchestrating the cell identity of FN-RMS, and the modulation of MPC emerges as a key factor in redirecting FN-RMS towards a quiescent, non-tumorigenic state.

2024-11-27 | GSE282611 | GEO

A multitargeting approach rewires cell identity in fusion-negative rhabdomyosarcoma [bulk_ATACseq]

Project description:A multitargeting approach rewires cell identity in fusion-negative rhabdomyosarcoma [bulk_ATACseq]

| PRJNA1152883 | ENA

A multitargeting approach rewires cell identity in fusion-negative rhabdomyosarcoma [Human_RNAseq_bulk]

Project description:A multitargeting approach rewires cell identity in fusion-negative rhabdomyosarcoma [Human_RNAseq_bulk]

| PRJNA1152875 | ENA

A multitargeting approach rewires cell identity in fusion-negative rhabdomyosarcoma [Mouse_RNAseq_bulk]

Project description:A multitargeting approach rewires cell identity in fusion-negative rhabdomyosarcoma [Mouse_RNAseq_bulk]

| PRJNA1152882 | ENA

A multitargeting approach rewires cell identity in fusion-negative rhabdomyosarcoma [Human_RNAseq_bulk]

2024-09-03 | GSE275734 | GEO

A multitargeting approach rewires cell identity in fusion-negative rhabdomyosarcoma [bulk_ATACseq]

2024-09-03 | GSE275736 | GEO

A multitargeting approach rewires cell identity in fusion-negative rhabdomyosarcoma [Mouse_RNAseq_bulk]

2024-09-03 | GSE275735 | GEO

A multitargeting approach rewires cell identity in fusion-negative rhabdomyosarcoma

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-09-03 | GSE276201 | GEO

MEK inhibition rewires enhancer landscapes in RAS-driven Rhabdomyosarcoma to unlock a myogenic differentation block

Project description:Trametinib-treated rhabdomyosarcoma cells undergo transcriptional reprogramming akin to myogenic differentiation. This reprogramming is induced by loss of ERK-mediated inhibition of MYOG expression. Restoration of MYOG allows establishment of super-enhancers at genes expressed by terminally differentiated myotubes. Our findings demonstrate that aberrant MAP kinase activity blocks differentiation in rhabdomyosarcoma and highlight trametinib as a potential therapeutic for RAS-mutated rhabdomyosarcoma.

2018-04-01 | GSE85170 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data